EPIDERMAL ANTIBODY-IFA (L)

The epidermal antibody test is a blood test that detects circulating autoantibodies against proteins of the epidermis. It aids diagnosis and monitoring of autoimmune blistering skin diseases (such as pemphigus and pemphigoid). Results are interpreted with clinical exam and skin biopsy/direct immunofluorescence; a positive result supports the diagnosis and antibody titres can help track disease activity and treatment response.

The IFA (indirect immunofluorescence assay) detects antibodies in patient serum by incubating the serum on antigen-coated slides, then applying a fluorescent anti-human antibody. Bound patient antibodies produce fluorescence visible under a microscope. IFA gives qualitative and semi‑quantitative (titer) results and is commonly used for diagnosing autoimmune conditions (e.g., ANA) and certain infections; results need proper controls and clinical correlation.

Pemphigus testing looks for IgG autoantibodies against epidermal cell-surface proteins—primarily desmoglein 3 and desmoglein 1—using ELISA and indirect immunofluorescence. Direct immunofluorescence of skin or mucosa shows intercellular IgG and C3 deposits. Less commonly, antibodies to desmocollins or other keratinocyte surface antigens may be detected in atypical cases. Results correlate with disease severity and guide treatment.

An epidermal antibody test detects autoantibodies targeting skin (epidermal) structures, often used for blistering autoimmune diseases. "With reflex to titer" means a positive screening result automatically triggers serial dilutions to determine the antibody titer (endpoint). The titer quantifies antibody levels, aiding diagnosis, assessing disease activity, and guiding treatment or monitoring response.

If an antibody test is positive, it means your immune system has produced antibodies from past infection or vaccination. It does not confirm current infection or precise protection level; immunity may be partial and can wane over time. No immediate treatment is usually needed, but continue public-health measures and consult a clinician for further testing (e.g., PCR if symptomatic) or personalized advice.

Pemphigus vulgaris is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (and often desmoglein 1), proteins in desmosomes that bind skin and mucous membrane cells together. Antibody binding disrupts cell adhesion (acantholysis), producing painful blisters and erosions. Genetic susceptibility and triggers such as certain drugs or infections may contribute to disease onset.